Bronte Capital Management Pty Ltd. Decibel Therapeutics, Inc. Transaction History

Bronte Capital Management Pty Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	SELL	$2.41 - $4.81 $6,210 - $12,395	-2,577 Reduced 1.64%	154,878 $596,000
Q1 2023 May 12, 2023	SELL	$2.08 - $4.79 $4,056 - $9,340	-1,950 Reduced 1.22%	157,455 $475,000
Q4 2022 Feb 13, 2023	SELL	$1.86 - $3.54 $7,704 - $14,662	-4,142 Reduced 2.53%	159,405 $327,000
Q2 2022 Aug 08, 2022	BUY	$1.85 - $4.21 $597 - $1,359	323 Added 0.2%	163,547 $689,000
Q1 2022 May 13, 2022	BUY	$2.83 - $5.03 $17,002 - $30,220	6,008 Added 3.82%	163,224 $496,000
Q4 2021 Feb 10, 2022	SELL	$4.57 - $8.58 $10,264 - $19,270	-2,246 Reduced 1.41%	157,216 $731,000
Q2 2021 Aug 09, 2021	BUY	$6.39 - $11.51 $1.02 Million - $1.84 Million	159,462 New	159,462 $1.37 Million

Ticker DBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,964,500
Description
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to...

Get notified when there are updates to the investment portfolio of Bronte Capital Management Pty Ltd., based on Form 13F filings with the SEC.

Stay updated on Bronte Capital Management Pty Ltd. with notifications on news.